ConductScience.org, home

Paper41276263

Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.

Bergman H and 12 others. Cochrane Database Syst Rev, 2025. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Papers, record 41276263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41276263

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.
PubMed
Journal
Cochrane Database Syst Rev
PubMed
Year
2025
PubMed
Publication types
Journal Article, Systematic Review, Network Meta-Analysis
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
5.4, provisional
iCite
Revised in PubMed
2026-09-26
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bergman HHannahttps://orcid.org/0000-0002-5449-6844
2Henschke NNicholas
3Arevalo-Rodriguez IIngrid
4Buckley BSBrian S
5Crosbie EJEmma J
6Davies JCJennifer C
7Dwan KKerry
8Golder SPSu P
9Loke YKYoon Kong
10Probyn KKatrin
11Petkovic JJennifer
12Villanueva GGemma
13Morrison JJo

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Papillomavirus VaccinesMajor topic
Uterine Cervical NeoplasmsMajor topic
Papillomavirus InfectionsMajor topic
Humans
Female
Randomized Controlled Trials as Topic
Male
Adult
Adolescent
Middle Aged
Young Adult
Bias
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Child
Human Papillomavirus Viruses

Source PubMed

Download CSV of topics

Trials53

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00090285An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)Derived from the trialYesClinicalTrials.gov
NCT00122681Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18Derived from the trialYesClinicalTrials.gov
NCT00196924Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.Derived from the trialYesClinicalTrials.gov
NCT00290277Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 YearsDerived from the trialYesClinicalTrials.gov
NCT00294047Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and OlderDerived from the trialYesClinicalTrials.gov
NCT00306241A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsDerived from the trialYesClinicalTrials.gov
NCT00309166Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.Derived from the trialYesClinicalTrials.gov
NCT00316693Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 VaccineDerived from the trialYesClinicalTrials.gov
NCT00344032Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian WomenDerived from the trialYesClinicalTrials.gov
NCT00345878Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 YearsDerived from the trialYesClinicalTrials.gov
NCT00365378Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)Derived from the trialYesClinicalTrials.gov
NCT00365716Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)Derived from the trialYesClinicalTrials.gov
NCT00423046Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of AgeDerived from the trialYesClinicalTrials.gov
NCT00426361Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female SubjectsDerived from the trialYesClinicalTrials.gov
NCT00481767Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.Derived from the trialYesClinicalTrials.gov
NCT00485732A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 YearsDerived from the trialYesClinicalTrials.gov
NCT00496626An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)Derived from the trialYesClinicalTrials.gov
NCT00501137A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus VaccineDerived from the trialYesClinicalTrials.gov
NCT00520598Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)Derived from the trialYesClinicalTrials.gov
NCT00534638Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy AdolescentsDerived from the trialClinicalTrials.gov

See all 53 trialsDownload CSV of trials

References293

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134780705Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.Lancet Infect Dis2022https://conductscience.org/library/papers/34780705PubMed
220413076Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.J Adolesc Health2010https://conductscience.org/library/papers/20413076PubMed
329424799Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.Pediatr Infect Dis J2018https://conductscience.org/library/papers/29424799PubMed
438043220British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: An update on recommendations for practice 2023.Eur J Obstet Gynecol Reprod Biol2024https://conductscience.org/library/papers/38043220PubMed
530249615Challenges of independent assessment of potential harms of HPV vaccines.BMJ2018https://conductscience.org/library/papers/30249615PubMed
631742639Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015.J Natl Cancer Inst2020https://conductscience.org/library/papers/31742639PubMed
731755549Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.Cochrane Database Syst Rev2019https://conductscience.org/library/papers/31755549PubMed
831551002Safety and efficacy of human papillomavirus vaccination for people living with HIV: A systematic review and meta-analysis.Int J STD AIDS2019https://conductscience.org/library/papers/31551002PubMed
927697753Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective.BMJ2016https://conductscience.org/library/papers/27697753PubMed
1023770335
A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years.
Vaccine2013https://conductscience.org/library/papers/23770335PubMed
1120139221Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.J Natl Cancer Inst2010https://conductscience.org/library/papers/20139221PubMed
1235358015The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.Hum Vaccin Immunother2022https://conductscience.org/library/papers/35358015PubMed
1321629249End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.Br J Cancer2011https://conductscience.org/library/papers/21629249PubMed
1424055350Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.Vaccine2014https://conductscience.org/library/papers/24055350PubMed
1526467666Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection.J Natl Cancer Inst2016https://conductscience.org/library/papers/26467666PubMed
1638049621Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results.Nat Med2023https://conductscience.org/library/papers/38049621PubMed
1736855835Attitudes to reducing cervical screening frequency among UK women: A qualitative analysis.Psychooncology2023https://conductscience.org/library/papers/36855835PubMed
1821734063
Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
Clin Vaccine Immunol2011https://conductscience.org/library/papers/21734063PubMed
1931829767Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.Hum Vaccin Immunother2020https://conductscience.org/library/papers/31829767PubMed
2027354258A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men.Vaccine2016https://conductscience.org/library/papers/27354258PubMed

See all 293 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42724481Survival outcomes of postoperative radiotherapy and chemotherapy in early-stage cervical cancer: a Surveillance, Epidemiology, and End Results database-based stratified analysis.Transl Cancer Res2026https://conductscience.org/library/papers/42724481PubMed
42698614Willingness to receive cross-border human papillomavirus vaccination among Chinese male university students: a cross-sectional study with statistical indirect-association analysis.Front Public Health2026https://conductscience.org/library/papers/42698614PubMed
42506658Human Papillomavirus Vaccine Intent and Associated Factors Among the Unvaccinated University Freshmen in the Largest University Town in China.Vaccines (Basel)2026https://conductscience.org/library/papers/42506658PubMed
42453778Real-world Impact of HPV Vaccination on CIN2+ Reduction: A Meta-analysis of Observational Studies Assessing Variation by Age, Coverage, and Vaccine Type.Open Forum Infect Dis2026https://conductscience.org/library/papers/42453778PubMed
42449659HPV-Related Disease: Gynecologists' Leadership in Patient-Centered Multidisciplinary Care.Cancers (Basel)2026https://conductscience.org/library/papers/42449659PubMed
42415479Moving Beyond the Female-Only Paradigm: Arguments for Accelerating the Global Gender-Neutral Human Papillomavirus Vaccination.Cancer Control2026https://conductscience.org/library/papers/42415479PubMed
42409728The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.Hum Vaccin Immunother2026https://conductscience.org/library/papers/42409728PubMed
42334459Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.Hum Vaccin Immunother2026https://conductscience.org/library/papers/42334459PubMed
41877638Correcting what cannot be corrected: rethinking publication bias analysis methods in clinical meta-analyses.Korean J Anesthesiol2026https://conductscience.org/library/papers/41877638PubMed
41724739HPV vaccination willingness and its determinants among male university students post-approval of male-specific HPV vaccines in China: a large-scale cross-sectional study.BMC Public Health2026https://conductscience.org/library/papers/41724739PubMed
41276264Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/41276264PubMed
41276263Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/41276263PubMed
40900298FIGO position statement on the effectiveness and safety of the HPV vaccine.Int J Gynaecol Obstet2025https://conductscience.org/library/papers/40900298PubMed
40687764Factors associated with the intention to vaccinate and price sensitivity to the human papillomavirus (HPV) vaccine among Chinese male medical college students: a cross-sectional survey.PeerJ2025https://conductscience.org/library/papers/40687764PubMed

Download CSV of cited by

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGENCHEMBL4297973Derived from the trial3https://conductscience.org/library/drugs/CHEMBL4297973ChEMBL
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLESCHEMBL6068359Derived from the trial4https://conductscience.org/library/drugs/CHEMBL6068359ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41276263

GET https://conductscience.org/api/papers/v1/41276263/trials?page=2